Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel potential therapies for obesity discovered at Bristol-Myers Squibb

May 4, 2012

Azelon completes phase II study of nasal spray for osteoporosis

May 3, 2012

Enrollment complete in pivotal study of oral testosterone replacement therapy

May 3, 2012

E.U. grant issued to support development of drug for fetal growth restriction

May 2, 2012

FDA approves new therapy for type 1 Gaucher's disease

May 2, 2012

FDA accepts lomitapide NDA for review

May 2, 2012

New diacylglycerol O-acyltransferase 1 inhibitors designed

May 2, 2012

Trimel gives update on special population study of male hypogonadism treatment

April 30, 2012

FDA approves new product to treat erectile dysfunction

April 30, 2012

Proximagen designs novel chemokine CCR2 receptor antagonists

April 30, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...